Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2

Pigment Cell and Melanoma Research

Volumn 28, Issue 1, 2015, Pages 73-81

  Borsotti, Patrizia ^a   Ghilardi, Carmen ^a   Ostano, Paola ^b   Silini, Antonietta ^a   Dossi, Romina ^a   Pinessi, Denise ^a   Foglieni, Chiara ^a   Scatolini, Maria ^b   Lacal, Pedro M ^c   Ferrari, Raffaele ^d   Moscatelli, Davide ^d   Sangalli, Fabio ^a   D'Atri, Stefania ^c   Giavazzi, Raffaella ^a   Bani, Maria Rosa ^a   Chiorino, Giovanna ^b   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Laboratory of Cancer Genomics   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d POLITECNICO DI MILANO   (Italy)

Author keywords

Cell motility; FGF 2; Melanoma; Metastasis; Slug; Thrombospondin 1; VEGFR 1

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR SLUG; VASCULOTROPIN RECEPTOR 1; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GROWTH; CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CUTANEOUS MELANOMA; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA CELL LINE; MELANOMA METASTASIS; PHENOTYPE; PROTEIN EXPRESSION; 3T3 CELL LINE; ANIMAL; CELL MOTION; GENE REGULATORY NETWORK; LUNG; MELANOMA; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; FIBROBLAST GROWTH FACTOR 2; GENE REGULATORY NETWORKS; HUMANS; LUNG; MELANOMA; MICE; NEOPLASM METASTASIS; NIH 3T3 CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; THROMBOSPONDIN 1; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84919608603     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12319     Document Type: Article

References (46)

1. Adams, J.C., and Lawler, J. (2011). The thrombospondins. Cold Spring Harb Perspect. Biol. 3, a009712.
2. Baumgartner, J.M., Palmer, B.E., Banerjee, A., and Mccarter, M.D. (2008). Role of melanoma secreted thrombospondin-1 on induction of immunosuppressive regulatory T cells through CD47. J. Cancer Mol. 4, 145-152.
3. Bornstein, P., and Sage, E.H. (2002). Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14, 608-616.
4. Cheadle, C., Vawter, M.P., Freed, W.J., and Becker, K.G. (2003). Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73-81.
5. De Fraipont, F., Keramidas, M., El Atifi, M., Chambaz, E.M., Berger, F., and Feige, J.J. (2004). Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization. Oncogene 23, 3642-3649.
6. Dhasarathy, A., Phadke, D., Mav, D., Shah, R.R., and Wade, P.A. (2011). The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS ONE 6, e26514.
7. Donoviel, D.B., Amacher, S.L., Judge, K.W., and Bornstein, P. (1990). Thrombospondin gene expression is associated with mitogenesis in 3T3 cells: induction by basic fibroblast growth factor. J. Cell. Physiol. 145, 16-23.
8. Firlej, V., Mathieu, J.R., Gilbert, C. et al. (2011). Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res. 71, 7649-7658.
9. Ghilardi, C., Chiorino, G., Dossi, R., Nagy, Z., Giavazzi, R., and Bani, M. (2008). Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 9, 201.
10. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
11. Gupta, P.B., Kuperwasser, C., Brunet, J.P., Ramaswamy, S., Kuo, W.L., Gray, J.W., Naber, S.P., and Weinberg, R.A. (2005). The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047-1054.
12. Haqq, C., Nosrati, M., Sudilovsky, D. et al. (2005). The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102, 6092-6097.
13. Helfrich, I., and Schadendorf, D. (2011). Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? Mol. Oncol. 5, 137-149.
14. Herlyn, M. (1990). Human melanoma: development and progression. Cancer Metastasis Rev. 9, 101-112.
15. Herlyn, M., Thurin, J., Balaban, G. et al. (1985). Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 45, 5670-5676.
16. Kawataki, T., Naganuma, H., Sasaki, A., Yoshikawa, H., Tasaka, K., and Nukui, H. (2000). Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 20, 161-169.
17. Kazerounian, S., Yee, K.O., and Lawler, J. (2008). Thrombospondins in cancer. Cell. Mol. Life Sci. 65, 700-712.
18. Kudo-Saito, C., Shirako, H., Takeuchi, T., and Kawakami, Y. (2009). Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195-206.
19. Lacal, P.M., Failla, C.M., Pagani, E., Odorisio, T., Schietroma, C., Falcinelli, S., Zambruno, G., and D'atri, S. (2000). Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol. 115, 1000-1007.
20. Lacal, P.M., Ruffini, F., Pagani, E., and D'atri, S. (2005). An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int. J. Oncol. 27, 1625-1632.
21. Lawler, J., and Detmar, M. (2004). Tumor progression: the effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 36, 1038-1045.
22. Lee, Y.J., Koch, M., Karl, D., Torres-Collado, A.X., Fernando, N.T., Rothrock, C., Kuruppu, D., Ryeom, S., Iruela-Arispe, M.L., and Yoon, S.S. (2010). Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res. 70, 948-956.
23. MacDougall, J.R., Bani, M.R., Lin, Y., Muschel, R.J., and Kerbel, R.S. (1999). 'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br. J. Cancer 80, 504-512.
24. Mcclenic, B.K., Mitra, R.S., Riser, B.L., Nickoloff, B.J., Dixit, V.M., and Varani, J. (1989). Production and utilization of extracellular matrix components by human melanocytes. Exp. Cell Res. 180, 314-325.
25. Miller, A.J., and Mihm, M.C. Jr (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
26. National Research, C. (2011). Guide for the Care and Use of Laboratory Animals, 8th edn. (Washington, DC: The National Academies Press).
27. Naumov, G.N., Bender, E., Zurakowski, D. et al. (2006). A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst. 98, 316-325.
28. Newkirk, K.M., Mackenzie, D.A., Bakaletz, A.P., Hudson, L.G., and Kusewitt, D.F. (2008). Microarray analysis demonstrates a role for Slug in epidermal homeostasis. J. Invest. Dermatol. 128, 361-369.
29. Nucera, C., Porrello, A., Antonello, Z.A. et al. (2010). B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl Acad. Sci. USA 107, 10649-10654.
30. Peng, H.H., Liang, S., Henderson, A.J., and Dong, C. (2007). Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp. Cell Res. 313, 551-559.
31. Riker, A.I., Enkemann, S.A., Fodstad, O. et al. (2008). The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics 1, 13.
32. Rofstad, E.K., Henriksen, K., Galappathi, K., and Mathiesen, B. (2003). Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res. 63, 4055-4061.
33. Satyamoorthy, K., Dejesus, E., Linnenbach, A.J., Kraj, B., Kornreich, D.L., Rendle, S., Elder, D.E., and Herlyn, M. (1997). Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 7(Suppl 2), S35-S42.
34. Scatolini, M., Grand, M.M., Grosso, E., Venesio, T., Pisacane, A., Balsamo, A., Sirovich, R., Risio, M., and Chiorino, G. (2010). Altered molecular pathways in melanocytic lesions. Int. J. Cancer 126, 1869-1881.
35. Shirley, S.H., Greene, V.R., Duncan, L.M., Torres Cabala, C.A., Grimm, E.A., and Kusewitt, D.F. (2012). Slug expression during melanoma progression. Am. J. Pathol. 180, 2479-2489.
36. Silini, A., Ghilardi, C., Ardinghi, C., Bernasconi, S., Oliva, P., Carraro, F., Naldini, A., Bani, M.R., and Giavazzi, R. (2010). Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clin. Exp. Metastasis 27, 43-53.
37. Straume, O., and Akslen, L.A. (2001). Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am. J. Pathol. 159, 223-235.
38. Talantov, D., Mazumder, A., Yu, J.X., Briggs, T., Jiang, Y., Backus, J., Atkins, D., and Wang, Y. (2005). Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234-7242.
39. Taraboletti, G., Roberts, D.D., and Liotta, L.A. (1987). Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J. Cell Biol. 105, 2409-2415.
40. Trapp, V., Parmakhtiar, B., Papazian, V., Willmott, L., and Fruehauf, J.P. (2010). Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 13, 305-315.
41. Tucker, R.P., Hagios, C., Chiquet-Ehrismann, R., Lawler, J., Hall, R.J., and Erickson, C.A. (1999). Thrombospondin-1 and neural crest cell migration. Dev. Dyn. 214, 312-322.
42. Tuszynski, G.P., and Nicosia, R.F. (1996). The role of thrombospondin-1 in tumor progression and angiogenesis. BioEssays 18, 71-76.
43. Tuszynski, G.P., Gasic, T.B., Rothman, V.L., Knudsen, K.A., and Gasic, G.J. (1987). Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 47, 4130-4133.
44. Vikhanskaya, F., Bani, M.R., Borsotti, P., Ghilardi, C., Ceruti, R., Ghisleni, G., Marabese, M., Giavazzi, R., Broggini, M., and Taraboletti, G. (2001). p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 20, 7293-7300.
45. Yee, K.O., Connolly, C.M., Duquette, M., Kazerounian, S., Washington, R., and Lawler, J. (2009). The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res. Treat. 114, 85-96.
46. Zaki, K.A., Basu, B., and Corrie, P. (2012). The role of angiogenesis inhibitors in the management of melanoma. Curr. Top. Med. Chem. 12, 32-49.